Licencing Opportunity:
This work represents a licensing opportunity.
John Coffey, VP Business Development NanoBio Corporation Ann Arbor, Michigan, USA 734-302-9107
Related Industry Reports:
- World market for cancer vaccines 2007-2012
- Therapeutic Vaccines - A far-off promise of greatness
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Therapeutic Cancer Vaccines - A turbulent path from bench to bedside
- Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis
Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model.
Human vaccines 2010 Jul 17; In press
Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, Sutcliffe J, Baker J JR
NanoBio Corp., Ann Arbor, MI, USA. tarek.hamouda@nanobio.com.
Mutations of influenza virus increase concerns of worldwide epidemics resulting from the newly emergent strains. Current influenza vaccines are inefficient and require annual vaccinations. W(80)5EC adjuvant is an oil-in-water emulsion composed of nanodroplets with an average diameter of approximately 400 nm. The nanoemulsion adjuvant has been used successfully to stimulate the immune response when mixed with several other antigens in animal models. In this study, W(80)5EC nanoemulsion adjuvant activity was evaluated using nasal influenza vaccination in a murine model. Five to twenty percent W(80)5EC adjuvant was used to inactivate influenza A/Puerto Rico/8/34/05 (H1N1). Mice immunized with the nanoemulsion adjuvanted influenza virus intranasally showed a robust specific humoral immune response as demonstrated using ELISA and HAI assays. Serum HAI titers were more than 10(4) following two vaccinations. Vaccinated mice were also protected against challenge with an LD(80) of live influenza virus. Splenocytes from vaccinated mice were assayed for cytokine production following virus stimulation. The cytokine profile demonstrated a robust cellular immune response with enhanced Th1 and Th17 immunity that provided balanced immunity against both intracellular and extracellular forms of the virus. Additionally, the vaccine preparations showed minimal protein degradation but remained potent when stored at 4 degrees C for up to three months. This work demonstrates that W(80)5EC nanoemulsion adjuvant can effectively enhance the immunogenicity of influenza hemagglutinin antigen. The nanoemulsion adjuvant can result in antigen sparing and cross-protection. The potential exists for a nasally administered influenza vaccine that may require little or no refrigerated storage.
Keywords: intranasal vaccine influenza